Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04081220 · ClinicalTrials.gov registry record · Phase 2
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2
A Phase 2 study of Thrombocythemia, Essential, sponsored by The University of Texas Health Science Center at San Antonio.
- Active
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT04081220 is a Phase 2 study of Thrombocythemia, Essential that is active but no longer recruiting, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 9 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04081220, a Phase 2 study of Thrombocythemia, Essential, is active but no longer recruiting, sponsored by The University of Texas Health Science Center at San Antonio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.
Conditions Studied
Interventions
- DRUG IMG-7289
Study Locations (1)
Texas
- Mays Cancer Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-04-09 |
| Est. Completion | 2026-12-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04081220
The ClinicalTrials.gov registry entry for NCT04081220 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thrombocythemia, Essential appearing as the primary indexed condition, and to 1 intervention - of which IMG-7289 is the first listed.
NCT04081220 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04081220 about?
NCT04081220 is a clinical study titled "Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2". This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.
What is the current status of trial NCT04081220?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2020-04-09. Estimated completion is 2026-12-20.
What conditions does trial NCT04081220 study?
This clinical trial studies the following conditions: Thrombocythemia, Essential.
What interventions are being tested in trial NCT04081220?
The interventions under investigation include: IMG-7289 (DRUG).
Who is sponsoring clinical trial NCT04081220?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04081220 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombocythemia, Essential
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.